FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, namely to an antibody or an antigen-binding fragment thereof, which binds to thymic stromal lymphopoietin (TSLP), to a conjugate, a bispecific antibody, a pharmaceutical composition and a kit containing said conjugate, as well as to a method for production thereof. Also disclosed is an isolated nucleic acid molecule coding said antibody, as well as a cell and a vector containing same.
EFFECT: invention is effective for treating or preventing allergic inflammation or autoimmune disease in a patient, as well as for detecting the presence or level of TSLP in a sample.
47 cl, 9 dwg, 18 tbl, 22 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMAN TSLP ANTIBODIES AND USE THEREOF | 2021 |
|
RU2825460C1 |
| ANTI-CLDN-18.2 ANTIBODY AND USE THEREOF | 2021 |
|
RU2829997C1 |
| ANTI-FXI/FXIA ANTIBODY, ANTIGEN-BINDING FRAGMENT AND PHARMACEUTICAL APPLICATION THEREOF | 2021 |
|
RU2838408C1 |
| TETANUS TOXIN ANTIBODY AND USE THEREOF | 2020 |
|
RU2815280C1 |
| BISPECIFIC PROTEIN | 2019 |
|
RU2784486C1 |
| BISPECIFIC ANTIBODY AGAINST CD3E/BCMA AND ITS USE | 2019 |
|
RU2800164C2 |
| ANTIBODY TO B7-H4, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2792748C2 |
| ANTIBODY CAPABLE OF BINDING TO THYMIC STROMAL LYMPHOPOIETIN, AND USE THEREOF | 2020 |
|
RU2825304C2 |
| PHARMACEUTICAL COMPOSITION BASED ON ANTIBODY TO PD-L1 AND ITS APPLICATION | 2018 |
|
RU2766590C2 |
| CORRESPONDING TARGET FOR TREATING FIBROSING DISEASES AND USE THEREOF | 2021 |
|
RU2830698C1 |
